Merck Reports Initiation of BLA Filling for V920 (rVSV∆G-ZEBOV-GP) Under FDA for Ebola Zaire

 Merck Reports Initiation of BLA Filling for V920 (rVSV∆G-ZEBOV-GP) Under FDA for Ebola Zaire

Merck Reports Initiation of BLA Filling for V920 (rVSV∆G-ZEBOV-GP) Under FDA for Ebola Zaire

Shots:

  • The BLA filling is in response to the Breakthrough Therapy designation granted in 2016 to V920, taken alone or in combination to treat serious or life-threatening disease or condition
  • In 2014, Merck gained rights for V920 from NewLink Genetics Corporation which was initially developed by Public Health Agency of Canada’s National Microbiology Laboratory
  • V920 is an Ebola Vaccine currently evaluated in P-III. The BLA submission is expected to complete in 2019

Click here to read full press release/ article | Ref: Merck | Image: Traveltempters

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post